
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
The financial analysis indicates that GRI Bio Inc's current valuation is considered attractive due to a significant upside potential as derived from a net present value (NPV) analysis. The company is poised to address unmet medical needs in areas such as inflammatory and autoimmune disorders, particularly through its promising product candidates, GRI-0621 and GRI-0803. Furthermore, the annual increase in cases of idiopathic pulmonary fibrosis (IPF), with over 40,000 new diagnoses, underscores the growing demand for innovative treatments, enhancing the company's market potential.
Bears say
GRI Bio Inc reported a significant net loss of $3.9 million, translating to an earnings per share (EPS) of $(7.72), which was worse than both the company's estimates and the consensus projections. The company's financial challenges are exacerbated by multiple risks, including liquidity concerns, potential failure of its product candidates to achieve safety and efficacy in clinical trials, and difficulties in gaining regulatory approvals. Additionally, external factors such as competition, shifting macroeconomic conditions, and varying investor sentiment in the biotech sector further contribute to the negative outlook for GRI Bio's stock.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares